Skip to main content
. Author manuscript; available in PMC: 2012 Jun 28.
Published in final edited form as: Trends Pharmacol Sci. 2009 Dec;30(12):610–616. doi: 10.1016/j.tips.2009.09.003

Figure 2. Proposed scheme for choosing a salvage HAART regimen.

Figure 2

It may eventually be possible to calculate the IIP of a salvage regimen based on in vitro phenotypic analysis of the inhibition of a patient-derived virus by individual antiretroviral drugs. The amount of replication occurring in a patient may be calculated from the viral load as described in Box 1. The relationship between these values could identify regimens with the potential to control viral replication. This information, together with issues of drug toxicity and adherence, may help physicians to choose the optimal salvage regimen. In order to implement this approach, it will be necessary to understand understand the rules for computing the IIP of a combination from measurements on individual drugs. It should be noted that this approach does not take into account potential complexities resulting from the presence of minority resistant variants not detected in genotypic or phenotypic analysis. It also does not consider the potentially significant inter-patient variability the pharmacokinetics of antiretroviral drugs.